Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.
Raoul Charles CoombesP D BadmanJingky P Lozano-KuehneX LiuIain R J MacphersonI ZubairiRichard D BairdNitzan RosenfeldJavier García CorbachoNicola CrestiR PlummerA ArmstrongR AllertonDónal LandersH NicholasL McLellanA LimFlorent MouliereOlivier E PardoV FergusonMichael J SecklPublished in: Nature communications (2023)